PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA reduced its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report) by 15.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 571,583 shares of the company’s stock after selling 106,444 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.13% of PROCEPT BioRobotics worth $23,955,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Principal Financial Group Inc. boosted its stake in PROCEPT BioRobotics by 5.7% during the fourth quarter. Principal Financial Group Inc. now owns 10,588 shares of the company’s stock worth $444,000 after buying an additional 568 shares during the last quarter. Jump Financial LLC acquired a new position in shares of PROCEPT BioRobotics during the 4th quarter valued at about $201,000. Charles Schwab Investment Management Inc. grew its holdings in shares of PROCEPT BioRobotics by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 335,117 shares of the company’s stock valued at $14,045,000 after purchasing an additional 13,868 shares during the period. Lisanti Capital Growth LLC acquired a new stake in PROCEPT BioRobotics during the fourth quarter worth about $5,100,000. Finally, M&T Bank Corp raised its stake in PROCEPT BioRobotics by 17.8% during the fourth quarter. M&T Bank Corp now owns 10,513 shares of the company’s stock worth $441,000 after purchasing an additional 1,591 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Alaleh Nouri sold 30,432 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $62.97, for a total value of $1,916,303.04. Following the sale, the executive vice president now directly owns 62,472 shares in the company, valued at $3,933,861.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other PROCEPT BioRobotics news, CFO Kevin Waters sold 3,435 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $46.67, for a total value of $160,311.45. Following the sale, the chief financial officer now directly owns 49,416 shares of the company’s stock, valued at approximately $2,306,244.72. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Alaleh Nouri sold 30,432 shares of PROCEPT BioRobotics stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $62.97, for a total transaction of $1,916,303.04. Following the sale, the executive vice president now directly owns 62,472 shares of the company’s stock, valued at $3,933,861.84. The disclosure for this sale can be found here. Insiders sold a total of 72,651 shares of company stock worth $4,168,073 over the last 90 days. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Stock Performance

PRCT opened at $68.10 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 8.52 and a quick ratio of 7.44. The stock’s 50-day moving average price is $53.42 and its 200 day moving average price is $46.34. PROCEPT BioRobotics Co. has a 12-month low of $24.83 and a 12-month high of $77.00.

PROCEPT BioRobotics (NASDAQ:PRCTGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.04. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 41.35%. The business had revenue of $44.50 million during the quarter, compared to analyst estimates of $41.58 million. During the same quarter last year, the firm posted ($0.63) earnings per share. The business’s revenue for the quarter was up 82.4% compared to the same quarter last year. As a group, research analysts expect that PROCEPT BioRobotics Co. will post -1.93 EPS for the current fiscal year.

Analysts Set New Price Targets

PRCT has been the subject of a number of recent analyst reports. Piper Sandler raised their price target on shares of PROCEPT BioRobotics from $67.00 to $75.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. TD Cowen upped their price target on PROCEPT BioRobotics from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, May 6th. Finally, Truist Financial raised their price objective on PROCEPT BioRobotics from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $61.20.

Check Out Our Latest Stock Analysis on PROCEPT BioRobotics

PROCEPT BioRobotics Company Profile

(Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Featured Articles

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report).

Institutional Ownership by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.